natgillin/translations-raw huggingface dataset:
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the marketing authorisation for Solamocta can be granted provided that the recommended revised instructions on product administration and prudent use warnings are added to the product information.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da se dovoljenje za promet z zdravilom Solamocta lahko izda pod pogojem, da se v informacije o zdravilu vključijo priporočena revidirana navodila o načinu dajanja zdravila in opozorila o preudarni uporabi.
Eurovet Animal Health B.V. submitted a marketing authorisation application, under Article 13(3) of Directive 2001/82/EC (i.e. hybrid or mixed application), for Solamocta to the United Kingdom via the decentralised procedure referring to the reference product Amoxinsol 100% w/w Powder for Oral Solution authorised in the United Kingdom.
je po decentraliziranem postopku v Združenem kraljestvu predložilo vlogo za pridobitev dovoljenja za promet z zdravilom Solamocta v skladu s členom 13(3) Direktive 2001/82/ES (tj. hibridno ali mešano vlogo), ki se nanaša na referenčno zdravilo Amoxinsol 100 % m/m prašek za peroralno raztopino, odobreno v Združenem kraljestvu.
The Committee recommended revised instructions on product administration and advice on prudent use to address responsible use in relation to development of antimicrobial resistance.
Da bi spodbudil odgovorno uporabo v zvezi z razvojem protimikrobne odpornosti, je odbor priporočil revidirana navodila za dajanje zdravila in nasvet o preudarni uporabi.
Why was Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys reviewed?
Zakaj je bil opravljen pregled zdravila Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane?
What is Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys?
Kaj je zdravilo Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane?
Questions and answers on Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys (amoxicillin trihydrate)
Vprašanja in odgovori v zvezi z zdravilom Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane (amoksicilin trihidrat)
It usually disappeared spontaneously within 1 week at most.
Običajno je spontano izginila v največ enem tednu.
After reconstitution, each dose of 1 ml contains:
Po rekonstituciji vsak odmerek (1 ml) vsebuje:
Date of first authorisation: 03/05/2013 Date of last renewal: 20/03/2018
Datum pridobitve dovoljenja za promet: 03/05/2013 Datum zadnjega podaljšanja dovoljenja za promet: 20/03/2018
Efficacy of the treatment has not been investigated beyond 2 years following treatment.
Učinkovitost zdravljenja ni bila raziskana po preteku 2 let od zdravljenja.
ATC-vet code: QL03AX90.
Oznaka ATC vet: QL03AX90.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon
Če opazite kakršne koli resne stranske učinke ali druge učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite da zdravilo ni delovalo, obvestite svojega veterinarja.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (http://www.ema.europa.eu/.)
This was demonstrated in a field trial over a period of 2 years.
To je bilo potrjeno s terensko študijo v trajanju 2 let.
The virus expresses the IL-2 gene at the inoculation site, but does not replicate in the cat.
Virus izraža IL-2 gen na mestu inokulacije, vendar se v mački ne replicira.
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section 4.9.
Učinkovitost je bila preskušena le v povezavi z operativnim zdravljenjem in radioterapijo, zato je potrebno zdraviti v skladu s potekom zdravljenja, opisanim v poglavju 4.9.
Start the treatment course the day before radiation therapy, preferably within one month after surgical excision.
Zdravljenje začnite dan pred zdravljenjem z obsevanjem, če je le mogoče v enem mesecu po kirurški odstranitvi tumorja.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
A. IZDELOVALCI PROIZVAJALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN
Shelf life after first opening the immediate packaging: use immediately after reconstitution.
Rok uporabnosti po prvem odpiranju stične ovojnine: Uporabite takoj po rekonstituciji.
Lyophilisate: whitish homogeneous pellet.
Liofilizat: belkasta homogena peleta.
Mild local and/or systemic adverse reactions related to the injection itself may be observed transitorily.
Občasno se lahko prehodno pojavijo blagi lokalni in/ali sistemski neželeni učinki povezani s samim injiciranjem.
Canarypox recombinants are known to be safe for humans.
Rekombinantni pox virus kanarčkov je varen za ljudi.
As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance.
Ker varnost in učinkovitost ponovnega zdravljenja za preprečevanje ponovitve fibrosarkoma ni bilo raziskano, mora o ponovnem zdravljenju odločati veterinar na osnovi ocene razmerja med koristjo in tveganjem.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Pogostost neželenih učinkov je določena po naslednjem dogovoru: zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Treatment course: 4 administrations at 1-week intervals (day 0, day 7, day 14, day 21) followed by 2 administrations at 2-week intervals (day 35, day 49).
Potek zdravljenja: 4 odmerki v razmakih 1 tedna (dan 0, dan 7, dan 14 in dan 21), ki jim sledita 2 odmerka v razmaku 2 tednov (dan 35 in dan 49).
Collagen hydrolysate Casein hydrolysate Sodium chloride
Hidrolizat kolagena Hidrolizat kazeina Natrijev klorid
Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2.
Še več, mačji IL-2 ima v primerjavi s človeški IL-2 dokazano zelo nizko biološko aktivnost na človeške levkocite.
Efficacy has not been tested in cats with metastasis or lymph node involvement.
Učinkovitost ni bila preskušena pri mačkah z metastazami ali razširjenostjo bolezni na bezgavke.
After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days).
Po dveh letih po študiji, je bil povprečni čas do ponovitve bolezni pri mačkah, zdravljenih z Oncept IL-2, daljši (nad 730 dni) v primerjavi s kontrolno skupino (287 dni).
After reconstitution of the lyophilisate with the solvent, shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.
Po rekonstituciji liofilizata z vehiklom nežno pretresite in okrog mesta odstranitve tumorja 5-krat injicirajte zdravilo (po približno 0,2 ml); ena injekcija v vsakem kotu in ena injekcija na v centru 5 cm x 5 cm velikega kvadrata, lociranega na sredino kirurške brazgotine.
EXP {month/year} Use immediately after reconstitution.
EXP {mesec/leto} Po rekonstituciji uporabite takoj.
Lyophilisate: 6 x 1 dose Solvent: 6 x 1 ml
Liofilizat 6 x 1 odmerek Vehikel 6 x 1 ml
Name and address of the manufacturer of the biological active substance
Ime in naslov proizvajalcev biološke učinkovine
Solvent: Water for injections.
Vehikel: Voda za injiciranje
Disodium phosphate dihydrate Potassium dihydrogen phosphate.
Natrijev dihidrogenfosfat dihidrat Kalijev dihidrogenfosfat
A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Zato se za uporabo tega imunološkega zdravila pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera od primera.
Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, other immunostimulants.
Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe in imunomodulatorji, druga zdravila za spodbujanje imunske odzivnosti.
Specific mechanisms by which immunostimulation induces anti-tumoural activity is not known.
Specifični mehanizmi s katerimi imunostimulacija inducira protitumorsko delovanje, niso znani.
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini, razen z vehiklom, ki je priložen za uporabo s tem zdravilom za uporabo v veterinarski medicini.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini.
Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis).
Imunoterapija kot dodatna terapija operativnimu zdravljenjemu in radioterapiji pri mačkah s fibrosarkomom (2-5 cm v premeru) brez metastaz ali prizadetosti bezgavk, da se za zmanjša nevarnost povrnitve bolezni in podaljša časa do povrnitve bolezni (lokalna ponovitev ali metastaza).
Overdose (symptoms, emergency procedures, antidotes):
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno):
Oncept IL-2 injected into the tumour bed thus delivers in situ a low dose of feline interleukin-2, which stimulates antitumour immunity while avoiding toxicity associated with systemic treatment.
Oncept IL-2 tako zagotovi in situ nizek odmerek mačjega interleukina-2, ki stimulira protitumorsko imunost ter brez toksičnosti, ki je lahko posledica sistemskega dajanja.
Store in the original package in order to protect from light.
Zaščitite pred svetlobo.
SC Read the package leaflet before use.
SC Pred uporabo preberite navodilo za uporabo.
Oncept IL-2 treatment reduced the risk of relapse, from 6 months after the start of treatment, by approximately 56% after 1 year and 65% after 2 years.
6 esecev po začetku zdravljenja za približno 56% po 1 letu in 65% po dveh letih.
After reconstitution use immediately.
Uporabite takoj po rekonstituciji.
The vaccine strain vCP1338 is a recombinant canarypox virus expressing feline interleukin-2 (IL-2).
Cepni sev vCP1338 je rekombinantni poxvirus kanarčkov, ki izraža mačji interleukin-2 (IL-2).
Oncept IL-2 lyophilisate
Oncept IL-2 Liofilizat
For the full list of excipients, see section 6.1.
*ELISA infektivni odmerek 50% Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
A moderate local reaction (pain on palpation, swelling, scratching) occurred very commonly in safety studies.
Zelo pogosto se je v študijah varnosti pojavila zmerna lokalna reakcija (bolečina na otip, oteklina in srbenje).
After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, erythema or slight pain, and in some cases, heat at the injection site) may occur.
Po dajanju prevelikega odmerka (10 odmerkov), se lahko pojavijo prehodno zmerno do močneje povišana telesna temperatura, lahko pa tudi lokalne reakcije (oteklina, eritem ali rahla bolečina in v nekaterih primerih toplota na mestu injiciranja).
Oncept IL-2 lyophilisate and solvent for suspension for injection for cats
Oncept IL-2 liofilizat in vehikel za suspenzijo za injiciranje za mačke
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section “Dosage for each species, route and method of administration”.
Učinkovitost je bila preskušena le v povezavi z operativnim zdravljenjem in radioterapijo, zato je potrebno zdraviti v skladu s potekom zdravljenja, ki je opisan v poglavju « ODMERKI ZA
Use of the recommended mode of administration in 5 injection points is important for achieving efficacy of the product; injection in 1 point may lead to reduced efficacy (see section 4.9).
pri injiciranju na enem mestu lahko pride do manjše učinkovitosti (glejte poglavje 4.9).
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box of 6 vials of lyophilisate and 6 vials of solvent
PODATKI NA ZUNANJI OVOJNINI Škatla s 6 vialami liofilizata in 6 vialami vehikla
Solvent for Oncept IL-2
Vehikel za Oncept IL-2
Transient apathy and hyperthermia (above 39.5 °C) occurred commonly in field studies.
Lahko se pojavita prehodna apatija in povišana telesna temperatura (nad 39° C).
Name and address of the manufacturer responsible for batch release
Ime in naslov proizvajalcazdravila odgovornega za sproščanje serije
Cardboard box containing 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Škatla s 6 vialami liofilizata in 6 vialami vehikla.
In a randomized clinical study, cats from different origins presenting a fibrosarcoma without metastasis or lymph node involvement were included in two groups, one receiving the reference treatment - surgery and radiotherapy - and the other receiving Oncept IL-2 in addition to surgery and radiotherapy.
V klinični študiji so bile mačke različnega izvora s fibrosarkomom brez metastaz in prizadetosti limfnih žlez, razdeljene v dve skupini.
Type I glass vial with a butyl elastomer closure, sealed with an aluminium cap. Cardboard box of 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.
Viala iz stekla tipa I z butilelastomerno zaporko, zapečateno z aluminijastim pokrovčkom.
Feline interleukin-2 recombinant canarypox virus (vCP1338) ........................................ ≥ 106.0 EAID50
Rekombinantni pox virus kanarčkov (vCP1338), ki vsebuje mačji interleukin-2.............≥ 106.0 EAID*50
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PRILOGA II A. PROIZVAJALCI BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA,
QUANTITY OF THE ACTIVE SUBSTANCE(S)
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
Lyophilisate and solvent for suspension for injection
liofilizat in vehikel za suspenzijo za injiciranje za mačke
Active substance:
KOLIČINA UČINKOVINE
However, the low number of patients involved and other serious shortcomings in the design of the studies prevented any firm conclusions being drawn.
Vendar zaradi nizkega števila vključenih bolnikov in drugih resnih pomanjkljivosti pri zasnovi študij ni bilo možno sprejeti trdnih zaključkov.
Passion flower EMA/275240/2014
Zel zdravilne pasijonke EMA/275240/2014
Passion flower medicines should only be used in adults and adolescents over the age of 12 years.
Zdravila, ki vsebujejo zel zdravilne pasijonke, se smejo uporabljati samo pri odraslih in mladostnikih, starejših od 12 let.
This summary is not intended to provide practical advice on how to use medicines containing passion flower.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel zdravilne pasijonke.
Passion flower is the common name for the above-ground parts of the plant Passiflora incarnata L. The HMPC conclusions only cover passion flower preparations which are obtained by comminuting (reducing into tiny pieces) or powdering the dried above-ground parts or as dry and liquid extracts.
Zel zdravilne pasijonke je splošno ime za nadzemne dele rastline Passiflora incarnata L. Zaključki odbora HMPC zajemajo samo pripravke z zeljo zdravilne pasijonke, ki se pridobivajo z drobljenjem (zmanjševanjem na majhne delce) ali z drobljenjem posušenih nadzemnih delov v prah ter kot suhi ali tekoči ekstrakti.
Further information on the risks associated with these passion flower medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o tveganjih, povezanih s temi zdravili, ki vsebujejo zel zdravilne pasijonke, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Herbal medicines containing these passion flower preparations are usually available as herbal teas to be drunk or as solid or liquid forms to be taken by mouth.
Zdravila rastlinskega izvora, ki vsebujejo te pripravke z zeljo zdravilne pasijonke, so navadno na voljo kot zdravilni čaji, ki se popijejo, ali v tekoči ali trdni obliki za jemanje skozi usta.
The HMPC concluded that, on the basis of its long-standing use, these passion flower preparations can be used for the relief of mild symptoms of mental stress and to aid sleep.
Odbor HMPC je na podlagi dolgotrajne uporabe zaključil, da se lahko ti pripravki, ki vključujejo zel zdravilne pasijonke, uporabljajo za lajšanje blagih simptomov duševne obremenitve in kot pomoč pri spanju.
Passion flower preparations may also be found in combination with other herbal substances in some herbal medicines.
Pripravki z zeljo zdravilne pasijonke so v nekaterih zdravilih rastlinskega izvora lahko na voljo tudi v kombinaciji z drugimi rastlinskimi snovmi.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of passion flower.
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo zeli zdravilne pasijonke.
Any applications for the licensing of medicines containing passion flower have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo zel zdravilne pasijonke, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
Further information on the HMPC assessment of passion flower medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o oceni zdravil, ki vsebujejo zel zdravilne pasijonke, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
How are passion flower medicines approved in the EU?
Kako so zdravila, ki vsebujejo zel zdravilne pasijonke, odobrena v EU?
Information on the use and licensing of passion flower medicines in EU Member States should be obtained from the relevant national authorities.
Za informacije o uporabi in registraciji zdravil, ki vsebujejo zel zdravilne pasijonke, v državah članicah EU se obrnite na pristojni nacionalni organ.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing passion flower.
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo zel zdravilne pasijonke.
Other information about passion flower medicines
Druge informacije o zdravilih, ki vsebujejo zel zdravilne pasijonke
The HMPC conclusions on the use of these passion flower medicines for mild symptoms of mental stress and to aid sleep are based on their ‘traditional use' in these conditions.
Zaključki odbora HMPC o uporabi zdravil, ki vsebujejo zel zdravilne pasijonke, za blage simptome duševne obremenitve in kot pomoč pri spanju temeljijo na njihovi „tradicionalni uporabi“.
In its assessment, the HMPC also considered published clinical studies of passion flower medicines.
V svoji oceni je odbor HMPC prav tako upošteval objavljene klinične študije zdravil, ki vsebujejo zel zdravilne pasijonke.
What evidence supports the use of passion flower medicines?
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo zel zdravilne pasijonke?
Detailed instructions on how to take passion flower medicines and who can use them can be found in the package leaflet that comes with the medicine.
Podrobna navodila o jemanju zdravil, ki vsebujejo zel zdravilne pasijonke, in o tem, kdo sme ta zdravila jemati, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
For more information about treatment with passion flower medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravili, ki vsebujejo zel zdravilne pasijonke, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with passion flower medicines?
Kakšna tveganja so povezana z zdravili, ki vsebujejo zel zdravilne pasijonke?
Therefore, the HMPC conclusions on the use of passion flower medicines are based on their long-standing use.
Zaključki odbora HMPC v zvezi z uporabo zdravil, ki vsebujejo zel zdravilne pasijonke, zato temeljijo na njihovi dolgotrajni uporabi.
A doctor or a qualified healthcare practitioner should be consulted if the symptoms last for more than 2 weeks or worsen during the use of the medicine.
Če simptomi med uporabo zdravila trajajo več kot dva tedna ali se poslabšajo, se je
What is passion flower?
Kaj je zel zdravilne pasijonke?
For practical information about using passion flower medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
To obtain a dry extract the solvent is then evaporated.
Topilo se nato odpari, s čimer se pridobi suhi ekstrakt.
Passion flower
Zel zdravilne pasijonke
The main measure of effectiveness was the response to treatment after 16 weeks.
Glavno merilo učinkovitosti je bil odziv na zdravljenje po 16 tednih.
Further information of Targretin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije za zdravilo Targretin so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The response rates according to the 5 skin scores were 36% and 27%, respectively.
Stopnji odziva glede na pet kožnih karakteristik sta bili 36 % oz. 27 %.
Treatment should continue as long as the patient benefits from it.
Zdravljenje se nadaljuje, dokler je za bolnika koristno.
What measures are being taken to ensure the safe and effective use of Targretin?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Targretin?
The recommended starting dose is 300 mg/m2/day, taken as a single dose once a day with a meal.
Priporočeni začetni odmerek je 300 mg/m2/dan in se jemlje enkrat na dan pri obroku.